Table 2.

Summary of primary and secondary endpoints

	Placebo +  WBRT (N = 102)a	Veliparib 50 mg + WBRT (N = 103)		Veliparib 200 mg + WBRT (N = 102)
Median overall survival, days (95 % CI)	185 (137, 251)	209 (169, 264)	p = 0.933	209 (138, 255)	p = 0.909
Objective response rate, (%)	41.2	36.9	p = 0.535	42.2	p = 0.898
Median time to clinical brain metastasis progressiona, days (95 % CI)	348 (216, NR)	286 (192, NR)	p = 0.864	255 (204, 342)	p = 0.301
Median time to radiographic brain metastasis progressionb, days (95 % CI)	259 (184, NR)	226 (147, 360)	p = 0.314	224 (137, 358)	p = 0.536

p values (against placebo)

CI confidence interval, NR not reached, WBRT whole-brain radiation therapy

^aPer event review board

^bPer central imaging center